{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:09:26Z","timestamp":1793668166658,"version":"4.5.1"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec id=\"ab-noi240032-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>An accurate prognosis is especially pertinent in mild cognitive impairment (MCI), when individuals experience considerable uncertainty about future progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240032-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the prognostic value of tau positron emission tomography (PET) to predict clinical progression from MCI to dementia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240032-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a multicenter cohort study with external validation and a mean (SD) follow-up of 2.0 (1.1) years. Data were collected from centers in South Korea, Sweden, the US, and Switzerland from June 2014 to January 2024. Participant data were retrospectively collected and inclusion criteria were a baseline clinical diagnosis of MCI; longitudinal clinical follow-up; a Mini-Mental State Examination (MMSE) score greater than 22; and available tau PET, amyloid-\u03b2 (A\u03b2) PET, and magnetic resonance imaging (MRI) scan less than 1 year from diagnosis. A total of 448 eligible individuals with MCI were included (331 in the discovery cohort and 117 in the validation cohort). None of these participants were excluded over the course of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240032-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Tau PET, A\u03b2 PET, and MRI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240032-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Positive results on tau PET (temporal meta\u2013region of interest), A\u03b2 PET (global; expressed in the standardized metric Centiloids), and MRI (Alzheimer disease [AD] signature region) was assessed using quantitative thresholds and visual reads. Clinical progression from MCI to all-cause dementia (regardless of suspected etiology) or to AD dementia (AD as suspected etiology) served as the primary outcomes. The primary analyses were receiver operating characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240032-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the discovery cohort, the mean (SD) age was 70.9 (8.5) years, 191 (58%) were male, the mean (SD) MMSE score was 27.1 (1.9), and 110 individuals with MCI (33%) converted to dementia (71 to AD dementia). Only the model with tau PET predicted all-cause dementia (area under the receiver operating characteristic curve [AUC], 0.75; 95% CI, 0.70-0.80) better than a base model including age, sex, education, and MMSE score (AUC, 0.71; 95% CI, 0.65-0.77;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.02), while the models assessing the other neuroimaging markers did not improve prediction. In the validation cohort, tau PET replicated in predicting all-cause dementia. Compared to the base model (AUC, 0.75; 95% CI, 0.69-0.82), prediction of AD dementia in the discovery cohort was significantly improved by including tau PET (AUC, 0.84; 95% CI, 0.79-0.89;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), tau PET visual read (AUC, 0.83; 95% CI, 0.78-0.88;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.001), and A\u03b2 PET Centiloids (AUC, 0.83; 95% CI, 0.78-0.88;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.03). In the validation cohort, only the tau PET and the tau PET visual reads replicated in predicting AD dementia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi240032-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this study, tau-PET showed the best performance as a stand-alone marker to predict progression to dementia among individuals with MCI. This suggests that, for prognostic purposes in MCI, a tau PET scan may be the best currently available neuroimaging marker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.1612","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T11:02:44Z","timestamp":1718017364000},"page":"845","source":"Crossref","is-referenced-by-count":68,"title":["Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment"],"prefix":"10.1001","volume":"81","author":[{"given":"Colin","family":"Groot","sequence":"first","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Smith","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Department of Neurology, Sk\u00e5ne University Hospital, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyduine E.","family":"Collij","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, De Boelelaan, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Brain Imaging, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie E.","family":"Mastenbroek","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, De Boelelaan, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Brain Imaging, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa Pichet","family":"Binette","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Leuzy","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"},{"name":"Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Strandberg","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Hyoung","family":"Lyoo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[{"name":"Memory Clinic, Department of Rehabilitation and Geriatrics, Geneva University and University Hospitals, Geneva, Switzerland"},{"name":"Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora E.","family":"Peretti","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroimaging and Innovative Molecular Tracers, Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroimaging and Innovative Molecular Tracers, Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland"},{"name":"Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland"},{"name":"Center for Biomedical Imaging, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"La Joie","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memory and Aging Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Soleimani-Meigooni","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memory and Aging Center, University of California, San Francisco"},{"name":"Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Rabinovici","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memory and Aging Center, University of California, San Francisco"},{"name":"Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, California"},{"name":"Department of Radiology and Biomedical Imaging, University of California, San Francisco"},{"name":"Associate Editor, JAMA Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences in Malm\u00f6, Lund University, Lund, Sweden"},{"name":"Department of Neurology, Sk\u00e5ne University Hospital, Lund University, Lund, Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"noi240032r1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi240032r2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","article-title":"The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials.","volume":"84","author":"Sperling","year":"2014","journal-title":"Neuron"},{"issue":"10284","key":"noi240032r3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease.","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"noi240032r4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases.","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"noi240032r5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jama.2011.1992","article-title":"The central role of prognosis in clinical decision making.","volume":"307","author":"Gill","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"noi240032r6","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.v7.1","article-title":"Identifying relevant outcomes in the progression of Alzheimer\u2019s disease; what do patients and care partners want to know about prognosis?","volume":"7","author":"Mank","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"noi240032r7","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/alz.v19.6","article-title":"Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.","volume":"19","author":"Smith","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"8","key":"noi240032r8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","article-title":"Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging.","volume":"78","author":"Ossenkoppele","year":"2021","journal-title":"JAMA Neurol"},{"key":"noi240032r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101837","article-title":"Prediction of Alzheimer\u2019s disease dementia with MRI beyond the short-term: implications for the design of predictive models.","volume":"23","author":"Moscoso","year":"2019","journal-title":"Neuroimage Clin"},{"issue":"6","key":"noi240032r10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jalz.2014.03.006","article-title":"Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer\u2019s disease.","volume":"10","author":"Alexopoulos","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi240032r11","doi-asserted-by":"publisher","first-page":"16665","DOI":"10.1038\/s41598-020-73673-1","article-title":"PET amyloid in normal aging: direct comparison of visual and automatic processing methods.","volume":"10","author":"Haller","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"noi240032r12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2967\/jnumed.118.211532","article-title":"Assessing amyloid pathology in cognitively normal subjects using 18F-flutemetamol PET: comparing visual reads and quantitative methods.","volume":"60","author":"Collij","year":"2019","journal-title":"J Nucl Med"},{"issue":"22","key":"noi240032r13","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons.","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"noi240032r14","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac017","article-title":"Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk.","volume":"4","author":"Jack","year":"2022","journal-title":"Brain Commun"},{"issue":"2","key":"noi240032r15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers.","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"issue":"19","key":"noi240032r16","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"noi240032r17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"noi240032r18","doi-asserted-by":"publisher","first-page":"20S","DOI":"10.2967\/jnumed.121.263196","article-title":"Tau PET imaging in neurodegenerative disorders.","volume":"63","author":"Groot","year":"2022","journal-title":"J Nucl Med"},{"issue":"8","key":"noi240032r19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge.","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol Psychiatry"},{"issue":"6","key":"noi240032r20","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awz090","article-title":"A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer\u2019s disease dementia.","volume":"142","author":"Pontecorvo","year":"2019","journal-title":"Brain"},{"issue":"8","key":"noi240032r21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","article-title":"Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders.","volume":"77","author":"Leuzy","year":"2020","journal-title":"JAMA Neurol"},{"issue":"2","key":"noi240032r22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00259-019-04496-0","article-title":"Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948.","volume":"47","author":"Smith","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"noi240032r23","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s00259-021-05401-4","article-title":"A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.","volume":"48","author":"Leuzy","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"noi240032r24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/mds.v32.1","article-title":"[18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy.","volume":"32","author":"Whitwell","year":"2017","journal-title":"Mov Disord"},{"issue":"8","key":"noi240032r25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1212\/WNL.0000000000004264","article-title":"In vivo retention of 18F-AV-1451 in corticobasal syndrome.","volume":"89","author":"Smith","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"noi240032r26","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"noi240032r27","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","article-title":"Discriminative accuracy of [18F]flortaucipir positron emission tomography for alzheimer disease vs other neurodegenerative disorders.","volume":"320","author":"Ossenkoppele","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"noi240032r28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jalz.2019.08.201","article-title":"Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer\u2019s disease.","volume":"16","author":"Ossenkoppele","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"5","key":"noi240032r29","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jamaneurol.2019.5154","article-title":"Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological tau in patients with Alzheimer disease.","volume":"77","author":"Ossenkoppele","year":"2020","journal-title":"JAMA Neurol"},{"issue":"7","key":"noi240032r30","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1007\/s00259-021-05253-y","article-title":"The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers.","volume":"48","author":"Ashton","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"noi240032r31","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00259-020-05099-w","article-title":"The impact of demographic, clinical, genetic, and imaging variables on tau PET status.","volume":"48","author":"Ossenkoppele","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"noi240032r32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease.","volume":"13","author":"Jack","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi240032r33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi240032r34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/cercor\/bhn113","article-title":"The cortical signature of Alzheimer\u2019s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals.","volume":"19","author":"Dickerson","year":"2009","journal-title":"Cereb Cortex"},{"issue":"3","key":"noi240032r35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"issue":"1","key":"noi240032r36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13195-021-00880-x","article-title":"Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals.","volume":"13","author":"Biel","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"noi240032r37","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1212\/WNL.0000000000006075","article-title":"Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease.","volume":"91","author":"Aschenbrenner","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"noi240032r38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/jnnp-2021-328623","article-title":"Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer\u2019s disease.","volume":"93","author":"Lagarde","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"noi240032r39","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes.","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol"},{"issue":"18","key":"noi240032r40","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease.","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"noi240032r41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"noi240032r42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz2387","article-title":"A\u00df deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer\u2019s disease.","volume":"6","author":"Mattsson-Carlgren","year":"2020","journal-title":"Sci Adv"},{"issue":"3","key":"noi240032r43","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease.","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat Med"},{"issue":"19","key":"noi240032r44","doi-asserted-by":"publisher","first-page":"e2648","DOI":"10.1212\/WNL.0000000000010739","article-title":"Association of amyloid-\u00df CSF\/PET discordance and tau load 5 years later.","volume":"95","author":"Reimand","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"noi240032r45","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/brain\/awac329","article-title":"Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.","volume":"146","author":"Groot","year":"2023","journal-title":"Brain"},{"issue":"4","key":"noi240032r46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease.","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2819811\/jamaneurology_groot_2024_oi_240032_1723221555.47276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T11:01:39Z","timestamp":1723460499000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2819811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.1612","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}